Endocrinology, Vol 136, 2397-2403, Copyright © 1995 by Endocrine Society

ARTICLES

Bone morphogenetic protein-2 inhibits the synthesis of insulin-like growth factor-binding protein-5 in bone cell cultures

B Gabbitas and E Canalis
Department of Research, Saint Francis Hospital and Medical Center, Hartford, Connecticut 06105, USA.

Previous work from our laboratory indicated that bone morphogenetic protein-2 (BMP-2) enhances the synthesis of insulin-like growth factor- I (IGF-I) and IGF-II by skeletal cells. The activity of IGF-I and -II is regulated by six known IGF-binding proteins (IGFBPs). Although most IGFBP's inhibit the actions of IGF on bone growth, IGFBP-5 is stimulatory, and its synthesis correlates with changes in osteoblast cell growth. We tested the effects of BMP-2 on IGFBP-5 expression in cultures of osteoblast-enriched cells from 22-day-old fetal rat calvariae (Ob cells). Treatment of Ob cells with BMP-2 caused a time- and dose-dependent decrease in IGFBP-5 messenger RNA (mRNA) levels, as determined by Northern blot analysis. The effect was maximal after 24 h of treatment and occurred at BMP-2 concentrations of 0.03-3.3 nM. Treatment with BMP-2 for 24 h also decreased IGFBP-5 polypeptide levels in the extracellular matrix, as determined by Western blot analysis. The effects of BMP-2 on IGFBP-5 transcripts were independent of cell division, as they were observed in the presence and absence of hydroxyurea (1 mM). IGFBP-5 transcripts were barely detectable in the presence of the protein synthesis inhibitor cycloheximide at 3.6 microM, and further suppressive effects of BMP-2 on IGFBP-5 mRNA could not be determined. BMP-2 did not modify the decay of IGFBP-5 mRNA in transcriptionally arrested Ob cells. In addition, BMP-2 inhibited IGFBP- 5 heterogeneous nuclear RNA, determined by reverse transcription- polymerase chain reaction, after 2-6 h of treatment, suggesting an inhibition of IGFBP-5 transcription or processing. In conclusion, BMP-2 inhibits IGFBP-5 expression in Ob cells through pathways that are independent of its mitogenic activity and through mechanisms that may involve decreased transcription or altered RNA processing.

This article has been cited by other articles:

				E. Canalis, A. N. Economides, and E. Gazzerro Bone Morphogenetic Proteins, Their Antagonists, and the Skeleton Endocr. Rev., April 1, 2003; 24(2): 218 - 235. [Abstract] [Full Text] [PDF]

				T. A. Guise and G. R. Mundy Cancer and Bone Endocr. Rev., February 1, 1998; 19(1): 18 - 54. [Abstract] [Full Text]

				J. M. Hayden, D. D. Strong, D. J. Baylink, D. R. Powell, T. K. Sampath, and S. Mohan Osteogenic Protein-1 Stimulates Production of Insulin-Like Growth Factor Binding Protein-3 Nuclear Transcripts in Human Osteosarcoma Cells Endocrinology, October 1, 1997; 138(10): 4240 - 4247. [Abstract] [Full Text] [PDF]

				T. L. McCarthy, S. Casinghino, D. W. Mittanck, C.-H. Ji, M. Centrella, and P. Rotwein Promoter-dependent and -independent Activation of Insulin-like Growth Factor Binding Protein-5 Gene Expression by Prostaglandin E(2) in Primary Rat Osteoblasts J. Biol. Chem., March 22, 1996; 271(12): 6666 - 6671. [Abstract] [Full Text] [PDF]